Quarterly report · Q1

Period2023-01-01 → 2023-03-31
Filed2023-05-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥448.3bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Revenue¥1.74T2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥380.3bn2022-01-01 → 2022-03-31Cons.Revenue IFRS
Operating income¥76.8bn2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Operating income¥20.7bn2022-01-01 → 2022-03-31Cons.Operating profit loss IFRS
Profit before tax¥79.2bn2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Profit before tax¥173.0bn2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥31.0bn2022-01-01 → 2022-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥61.4bn2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥133.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥23.3bn2022-01-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥62.7bn2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Net income¥24.2bn2022-01-01 → 2022-03-31Cons.Profit loss IFRS
Total assets¥3.13Tat 2023-03-31Cons.Assets IFRS
Total assets¥3.10Tat 2022-12-31Cons.Assets IFRS
Total assets¥2.89Tat 2022-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥811.5bnat 2023-03-31Cons.Liabilities IFRS
Total liabilities¥840.3bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥2.32Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥2.10Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥2.05Tat 2021-12-31dCons.Equity IFRS
Equity (owners)¥2.28Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.23Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.07Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥477.1bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥423.4bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥410.7bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥71.9bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥211.8bn2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥57.7bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥35.8bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥81.6bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥22.8bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥32.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥95.5bn2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥34.6bn2022-01-01 → 2022-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥113.22023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥246.82022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥42.862022-01-01 → 2022-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥113.182023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥246.782022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥42.72022-01-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio72.8%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-03-31¥42.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-03-31¥33.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-03-31¥9.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-03-31¥3.7bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥9.7bn
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥9.7bn
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥13.0bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥4m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-03-31¥2.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥13m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥11.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥303.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥303.2bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥72.7bn
—segment totalrevenue2023-01-01 → 2023-03-31¥458.0bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥448.3bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥9.7bn
—segment totalsegment profit2023-01-01 → 2023-03-31¥89.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-01-01 → 2022-03-31¥39.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-01-01 → 2022-03-31¥30.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-01-01 → 2022-03-31¥8.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-01-01 → 2022-03-31¥4.1bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-03-31−¥8.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-03-31−¥8.8bn
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-03-31−¥11.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2022-01-01 → 2022-03-31¥7.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2022-01-01 → 2022-03-31¥7.7bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2022-01-01 → 2022-03-31¥3m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2022-01-01 → 2022-03-31−¥235m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2022-01-01 → 2022-03-31¥90.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2022-01-01 → 2022-03-31¥90.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2022-01-01 → 2022-03-31¥3m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2022-01-01 → 2022-03-31¥11.3bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2022-01-01 → 2022-03-31¥252.1bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2022-01-01 → 2022-03-31¥252.1bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2022-01-01 → 2022-03-31¥17.3bn
—segment totalrevenue2022-01-01 → 2022-03-31¥389.1bn
—segment totalrevenue external2022-01-01 → 2022-03-31¥380.3bn
—segment totalrevenue intersegment2022-01-01 → 2022-03-31¥8.8bn
—segment totalsegment profit2022-01-01 → 2022-03-31¥32.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 706
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任 あずさ監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)川 瀬 洋 人
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)鈴 木 専 行
Cpa3 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)松 尾 洋 孝
Number of submissionFilingDateInstant1
Revenue IFRS (5-year summary)Prior1YTDDuration380308000000JPY
Revenue IFRS (5-year summary)CurrentYTDDuration448344000000JPY
Revenue IFRS (5-year summary)Prior1YearDuration1737998000000JPY
Profit loss before tax IFRS (5-year summary)Prior1YTDDuration30985000000JPY
Profit loss before tax IFRS (5-year summary)CurrentYTDDuration79242000000JPY
Profit loss before tax IFRS (5-year summary)Prior1YearDuration172954000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YTDDuration23250000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)CurrentYTDDuration61430000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YearDuration133906000000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YTDDuration85041000000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)CurrentYTDDuration83148000000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YearDuration267980000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1QuarterInstant2069031000000JPY
Equity attributable to owners of parent IFRS (5-year summary)CurrentQuarterInstant2281415000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1YearInstant2225255000000JPY
Total assets IFRS (5-year summary)Prior1QuarterInstant2886042000000JPY
Total assets IFRS (5-year summary)CurrentQuarterInstant3132041000000JPY
Total assets IFRS (5-year summary)Prior1YearInstant3102638000000JPY
Basic earnings loss per share IFRS (5-year summary)Prior1YTDDuration42.86
Basic earnings loss per share IFRS (5-year summary)CurrentYTDDuration113.20
Basic earnings loss per share IFRS (5-year summary)Prior1YearDuration246.80
Diluted earnings loss per share IFRS (5-year summary)Prior1YTDDuration42.70
Diluted earnings loss per share IFRS (5-year summary)CurrentYTDDuration113.18
Diluted earnings loss per share IFRS (5-year summary)Prior1YearDuration246.78
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1QuarterInstant0.717
Ratio of owners equity to gross assets IFRS (5-year summary)CurrentQuarterInstant0.728
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1YearInstant0.717
Cash flows from used in operating activities IFRS (5-year summary)Prior1YTDDuration57698000000JPY
Cash flows from used in operating activities IFRS (5-year summary)CurrentYTDDuration71882000000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior1YearDuration211848000000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YTDDuration-22797000000JPY
Cash flows from used in investing activities IFRS (5-year summary)CurrentYTDDuration-35771000000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YearDuration-81575000000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YTDDuration-34561000000JPY
Cash flows from used in financing activities IFRS (5-year summary)CurrentYTDDuration-32659000000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YearDuration-95474000000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1QuarterInstant423362000000JPY
Cash and cash equivalents IFRS (5-year summary)CurrentQuarterInstant477137000000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1YearInstant471634000000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember557835617
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember557835617
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant557835617
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant557835617
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass